In the latest quarter, 7 analysts provided ratings for Eli Lilly LLY +1.30% Get Free Report , showcasing a mix of bullish and ...

Eli Lilly (NYSE:LLY) has been in the spotlight recently with a 3.96% share price increase over the past month. The selection ...

Our Top 5 Analyst Questions Eli Lilly’s Q1 Earnings Call Asad Haider (Goldman Sachs) asked about the impact of the CVS formulary loss on Zepbound’s market share and future PBM dynamics.

Pfizer faces a $1 billion sales hit in 2025 from IRA reforms, flat EPS and revenue forecasts, and long-term risks tied to patent expirations.

Health care stocks have outperformed so far in 2025 despite uncertainty surrounding the Donald Trump administration's ...

Investors soured on the sector when Elevance, an insurer, handed in disappointing results and shared a downbeat outlook.

Both Eli Lilly LLY and Merck MRK are major players in the U.S. pharmaceutical industry, developing and commercializing ...

J&J (NYSE:JNJ) stock surges rallying peers despite Trump's latest tariff threats on pharma as the company posts a quarterly ...

Johnson & Johnson shares jumped to their highest price in more than three months as the US-based healthcare group shrugged ...

Eli Lilly and Johnson & Johnson, PPH’s largest holdings, are facing unique challenges, impacting the ETF’s overall ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

HSBC Global Research has upgraded Divi's Laboratories Ltd. from a ‘reduce’ to a ‘buy’ rating, citing strong growth potential ...